Cookie policy

In this Cookie Policy, you will find information about the cookies used on kygevvi.com, a website in relation to UCB Global (the Website). The Website is operated by UCB S.A., a Belgian company with registered office at 60, Allée de la Recherche, 1070 Anderlecht (UCB, we or us).

This Cookie Policy applies to all webpages which form part of the Website.

Any personal data collected by UCB through cookies will be processed as set out in the UCB.com Website Privacy Policy, accessible here.

In this Cookie Policy, you will find more information on:

What cookies are and why UCB uses them;
The different types of cookies used on this Website.

To manage your cookie preferences, please visit the Privacy Preference Center, accessible at the bottom of every page of this Website. This Cookie Policy may be updated periodically. In that case, we will inform you of any significant changes by posting a prominent notice on the Website.

INDICATION

KYGEVVI is a prescription medicine used for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and children with a symptom onset on or before 12 years of age.

IMPORTANT SAFETY INFORMATION

KYGEVVI may cause serious side effects including elevated liver enzyme levels. Increased liver enzyme levels in your blood are common with KYGEVVI. Your healthcare provider will do blood tests to check your liver enzyme levels before starting treatment and during treatment with KYGEVVI.

Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including loss of appetite, pain on the right side of your stomach area, dark or amber-colored urine, yellowing of your skin or the white part of your eyes, nausea and vomiting, or itching.

KYGEVVI may cause stomach and intestinal (gastrointestinal) problems. Diarrhea and vomiting are common with KYGEVVI, but may also be severe and lead to hospitalization. Tell your healthcare provider right away if you have diarrhea or vomiting during treatment with KYGEVVI that lasts longer than a few days.

The most common side effects of KYGEVVI include diarrhea, stomach area (abdominal) pain including pain in the upper stomach area, vomiting, and increased liver enzyme levels in your blood.

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with KYGEVVI if you develop certain side effects.

Before taking or giving KYGEVVI, tell your healthcare provider about all of your medical conditions, including if you have or have had liver problems. In addition, tell your healthcare provider if you are pregnant or plan to become pregnant. It is not known if KYGEVVI will harm your unborn baby. Also, tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if KYGEVVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take KYGEVVI. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

These are not all of the possible side effects of KYGEVVI. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UCB, Inc. at UCBCares® (1-844-599-CARE [2273]).

Please see additional information in the Patient Information Leaflet.